Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Allogene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Allogene Therapeutics's regulatory disclosures and financial reporting.
Allogene Therapeutics, Inc. reports that investor and director Arie Belldegrun and affiliated entities have amended their passive ownership report. As of May 11, 2026, Dr. Belldegrun beneficially owns 13,610,578 shares of Allogene common stock, representing 3.9% of the 345,154,561 shares outstanding. His total includes 4,010,524 shares issuable within 60 days upon exercise of stock options and shares held through Bellco Legacy entities and Vida Ventures funds. The filing confirms that each reporting person now owns 5% or less of the outstanding common stock, with joint filing across the listed entities.
State Street Corporation reported beneficial ownership of 19,025,826 shares of Allogene Therapeutics, Inc. common stock on a Schedule 13G. This represents 5.5% of the class of Allogene’s common shares.
State Street reports no sole voting or dispositive power, with shared voting power over 18,772,433 shares and shared dispositive power over 19,025,826 shares. Subsidiaries involved include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.
Allogene Therapeutics President and CEO Zachary Roberts reported equity awards rather than open-market trades. He received a grant of 476,190 stock options to buy common stock at an exercise price of $2.11 per share, expiring on July 1, 2036. Twenty-five percent of these options vest on July 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Roberts was also granted 134,530 Restricted Stock Units, each representing one share of common stock. These RSUs vest in four equal annual installments over the four-year period starting July 20, 2026, subject to his continued service. The filing shows compensation-related acquisitions, with no reported stock purchases or sales in the market.
Allogene Therapeutics director Joshua A. Kazam reported equity compensation activity. On June 18, 2026, he exercised 47,700 Restricted Stock Units (RSUs), which converted into the same number of common shares, bringing his direct common stock holdings to 398,463 shares after the transactions.
On the same date he received a new award of 95,400 RSUs under the company’s 2018 plan. Each RSU represents a contingent right to receive one share of Allogene common stock, or cash at the company’s discretion, and will vest in two equal semi-annual installments over one year, subject to continued service.
MESSEMER DEBORAH M. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Deborah M. Messemer received a grant of 95,400 restricted stock units (RSUs). The award carries no purchase price and gives her the contingent right to receive 95,400 shares of Allogene common stock if the units vest.
According to the terms, the RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to her continued service through each vesting date. Following this grant, she holds 95,400 RSUs directly.
Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.
Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units. These RSUs give her the right to receive an equal number of Allogene common shares at future vesting dates, without paying an exercise price.
The award will vest in two equal semi-annual installments over one year from the grant date, as long as she continues to provide service through each vesting date. This filing does not report any open-market purchases or sales, only a compensation-related equity grant.
WITTE OWEN N. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Owen N. Witte received a grant of 95,400 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date.
Witte has elected to defer receipt of the underlying common shares until the earlier of 30 days after his separation from continuous service with the company or a change in control of Allogene, in line with the company’s Non-Employee Director Compensation Policy.
Humer Franz B reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Franz B. Humer received an equity grant of 95,400 restricted stock units. Each RSU represents a contingent right to one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to continued service.
The director has elected to defer receiving the common shares until the earlier of 30 days after leaving continuous service with the company or a change in control of Allogene.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics, Inc. director Elizabeth A. Barrett received a grant of 95,400 Restricted Stock Units. Each RSU represents a contingent right to one share of Allogene common stock.
The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to her continued service. Barrett has elected to defer delivery of the underlying shares until the earlier of 30 days after leaving continuous service or a change in control of the company.